News
24 September 2024
Continued Investment in Technology & Flexible Capacity, Including New Fill/Finish Capabilities, Fortify the Global Gene Therapy Support Offer at Ascend
London, United Kingdom – 24 September 2024 – Ascend Advanced Therapies (Ascend), a gene to GMP development partner, has...
Read More24 September 2024
The Logistics of Developing an Emerging Therapy
Developing emerging modalities such as cell and gene therapies presents many challenges from selecting the right approach to overcoming...
Read More17 September 2024
Building Reliability into Scale-Up: Targeted Optimization for AAV Production
Webinar with Sartorius Stedim Biotech Scaling up AAV production presents challenges that impact performance and product quality. In this...
Read More5 September 2024
It’s All About the Small Things
The quality of final drug products correlates directly with the quality of the raw materials, APIs, excipients, and manufacturing...
Read More3 September 2024
Gene therapy CDMOs play critical role in enabling AAV process improvement & standardization
Wes McConnell, CFO at Ascend The approval of numerous gene and gene-modified cell therapies by regulatory agencies around the...
Read More28 August 2024
Ascend Strengthens Operations with Two New Executive Team Hires
London, United Kingdom – 28 August 2024 – Ascend Advanced Therapies (Ascend), an end-to-end gene therapy development partner has...
Read More13 August 2024
Alliance for Regenerative Medicine (ARM) list of approved regenerative medicines
In 2024, we have more diversity in drug modalities than ever before. While small molecule and large molecule medicines...
Read More7 August 2024
How Can (Bio)pharmaceutical Companies Contribute to Improving Global Access to Essential Medications?
Industry experts were asked to weigh in on how companies can help to keep innovation and access open. Jason...
Read More5 August 2024
Contracting Out Frees Sponsors Up
Contract manufacturing organizations (CMOs), contract development and manufacturing organizations (CDMOs), and other contract organizations offer sponsor companies flexibility by...
Read More1 August 2024
Enhancing AAV production using high-throughput screens and rational design
Mo Mandegar, dPhil – Vice President and Head of Site, Alameda Adeno-associated viruses (AAVs) have emerged as a favored...
Read More23 July 2024
Advancing AAV production with high-throughput screening & transcriptomics
Christopher A Reid, Markus Hörer, Mohammad A Mandegar Recombinant adeno-associated viral (rAAV) vector manufacturing processes must be improved if...
Read More17 June 2024
The Importance of AAV Process Comparability Throughout Development
Relying on unscalable cell-culture processes during early stages can be fatal for product development. Markus Hörer, Chief Scientific Officer...
Read More